Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KAI-7535 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| KAI-7535: Dose Schedule 1 | EXPERIMENTAL | Participants will receive KAI-7535 once daily. |
| KAI-7535: Dose Schedule 2 | EXPERIMENTAL | Participants will receive KAI-7535 once daily. |
| KAI-7535: Dose Schedule 3 | EXPERIMENTAL | Participants will receive KAI-7535 once daily. |
| KAI-7535: Dose Schedule 4 | EXPERIMENTAL | Participants will receive KAI-7535 once daily. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to KAI-7535 once daily. |
| KAI-7535: Morning Dosing, Fed | EXPERIMENTAL | Participants will receive KAI-7535 in the morning following a meal on dosing days. |
| KAI-7535: Morning Dosing, Fasted | EXPERIMENTAL | Participants will receive KAI-7535 in the morning following an overnight fast on dosing days. |
| KAI-7535: Evening Dosing | EXPERIMENTAL | Participants will receive KAI-7535 in the evening on dosing days. |
| Name | Type | Description |
|---|---|---|
| KAI-7535 | DRUG | Oral tablets |
| Placebo | DRUG | Oral tablets |
Key Inclusion Criteria: * For participants without diabetes mellitus at screening and on Day 1, BMI ≥30 kilograms/square meter (kg/m\^2) or BMI ≥27 kg/m\^2 and a previous diagnosis of at least 1 of the following: * Hypertension * Dyslipidemia * Obstructive sleep apnea * Cardiovascular dise...
Top 20 of 37 competitors
KAI-7535 is an investigational oral small molecule developed by Kailera Therapeutics for the treatment of obesity. It is being studied in adults living with obesity or overweight, including those with at least one weight-related comorbidity. KAI-7535 is in Phase 2 clinical development and has not been approved by the FDA.
KAI-7535 targets the GLP-1 receptor, a receptor-class molecular target. It is a small molecule designed to act on this receptor and is being developed as an oral therapy for obesity. The GLP-1 receptor is the same target class associated with established incretin-based weight management approaches.
KAI-7535 is being developed by Kailera Therapeutics, Inc., which trades under the ticker KLRA. Kailera is the sponsor of the clinical program evaluating the drug in obesity and overweight. The company is advancing KAI-7535 as an oral small molecule candidate in the metabolic therapeutic area.
KAI-7535 is in Phase 2 clinical development for obesity. It is investigational and has not been approved by the FDA. The Phase 2 program includes a randomized, double-blind, placebo-controlled trial, and a completed Phase 1 study has also evaluated the drug in participants living with obesity or overweight.
KAI-7535 has been studied in two clinical trials. NCT07497880 is an active Phase 2 trial of oral KAI-7535 in adults with obesity or overweight and at least one weight-related comorbidity, enrolling 306 participants across the United States and Australia. NCT07294898 is a completed Phase 1 study with 18 participants in the United States.
KAI-7535 is an oral small molecule, meaning it is designed to be taken by mouth rather than injected. Its Phase 2 trial is titled as a study of oral KAI-7535 in adults living with obesity or overweight, and a completed Phase 1 study examined the effect of a low-fat meal and evening dosing on the drug.